RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

At a time that most of the Bio World is watching Alzheimer's results, the number of groups focused upon this RD trial are four:

1) BusDev people at various analgesia companies. They aren't likely purchasers.
2) Cortex Pharma. They probably can't buy at this point.
3) R&R--to see if they are going to be embarrassed. They do know Fact B (see below).
4) The iHub Cortex Board.

No one else really gives a damn, which brings me to Fact B:
There will be time to buy if there is positive news. The price might be 1.00-1.20, but that would be without risk.

So IMHO, the lack of volume doesn't say anything about general sentiment for or against trial prospects--it does say much about the lack of profile for Respiratory Depression at present. That would gradually change post-positive results, when the implications for pain programs would get some play, but it will be a partnering deal that will be the bigger valuation event.

NeuroInvestment